4.4 Review

Ace inhibitor therapy for heart failure in patients with impaired renal function: a review of the literature

Journal

HEART FAILURE REVIEWS
Volume 18, Issue 2, Pages 135-140

Publisher

SPRINGER
DOI: 10.1007/s10741-011-9295-6

Keywords

Heart failure; Cardiorenal; Ace inhibitor; Angiotensin receptor blocker; Acute kidney disease; Chronic kidney disease; Worsening renal function

Funding

  1. Bayer Schering Pharma AG
  2. DebioPharm S.A.
  3. Medtronic
  4. Novartis Pharma AG
  5. Otsuka Pharmaceuticals
  6. Sigma Tau
  7. Solvay Pharmaceuticals
  8. Pericor Therapeutics

Ask authors/readers for more resources

Heart failure syndromes are often associated with multi-organ dysfunction, and concomitant liver, renal, and neurologic involvement is very common. Neuro-hormonal antagonism plays a key role in the management of this syndrome, and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are one of the cornerstones of therapy. Cardiorenal physiology is becoming more recognized in these patients with advanced heart failure, and the role of neuro-hormonal blockade in this setting is vaguely defined in the literature. Often, angiotensin-converting enzyme inhibitors are decreased or even withheld in these circumstances. The purpose of this article is to review the role and pathophysiology of ace inhibition and angiotensin receptor blockade in patients with acute and chronic heart failure syndromes and concomitant cardiorenal physiology.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available